Accelerating a cure for 100M Long COVID patients. By incentivizing scientists, patients and supporters to collaborate and share data, we’re creating an open marketplace for rapid R&D and commercialization of new treatments for Long COVID. Our first treatment launches November 2024.
65 Million
Global Patient Population
14%
of Infections Resulting in Long COVID
$1 Trillion
Global Cost Yearly
Long COVID is the fastest-growing chronic health condition in human history.
14% of COVID infections result in Long COVID. The virus can be found in the body and brain for more than 200 days after the initial infection, making Long COVID a seriously unmet chronic disease....
Repurposing Existing Antivirals and Antibodies
Focusing on quickly testing and repurposing existing FDA-approved drugs, as well as Broadly Neutralizing Antibodies (bNAbs) to target persistent viral reservoirs in Long COVID patients.
Developing Long-Acting Antibody (LAAb) Therapies
Exploring research and trials for Long-Acting Antibody treatments that could prevent reinfection and manage viral persistence. These therapies could be integrated with COVID vaccines for dual protection.
Open Therapeutics Platform for Breakthrough Discoveries
Building an open platform for decentralized scientific collaboration to identify and test experimental, high-risk, high-reward therapies. This includes funding innovative ideas from researchers worldwide, enabled by DAO governance and resource sharing.
＠LongCOVIDlabs on 𝕏
Telegram community
Long COVID Labs (LCL) employs a multifaceted value capture model that combines near-term revenue generation with long-term innovation in therapeutics. By repurposing FDA-approved drugs like Paxlovid and leveraging existing antibody technologies, LCL ...
Nature
SARS-CoV-2 infection and persistence in the human body and brain at autopsy
NIH
More Than 50 Long-Term Effects of COVID-19: A Systematic Review and Meta-Analysis
New York Times
